scholarly journals Diabetic macro- and microvascular disease in type 2 diabetes

2007 ◽  
Vol 4 (2_suppl) ◽  
pp. S7-S11 ◽  
Author(s):  
Michel P Hermans

Before a patient develops overt type 2 diabetes mellitus, there is typically a prolonged period of patho-physiological change. In the common form of type 2 diabetes mellitus, there are years of insulin resistance, initially compensated by increased beta cell function, then impaired glucose tolerance develops, and finally type 2 diabetes. We know from studies such as the United Kingdom Prospective Diabetes Study (UKPDS) and the Belfast study that loss of beta cell function and insulin resistance are usually relentless.1, 2 Thus, therapy to reduce blood glucose has to be gradually increased with time for patients with diabetes. What is less well known is that every person has a different slope for beta cell function loss which intersects with insulin resistance.

2008 ◽  
Vol 32 (4) ◽  
pp. 310
Author(s):  
Kristy Wittmeier ◽  
Samatha Carey ◽  
Joanne Hamilton ◽  
Andrea Macintosh ◽  
Elizabeth Sellers ◽  
...  

2015 ◽  
Vol 2015 ◽  
pp. 1-6 ◽  
Author(s):  
Subrata Kumar Biswas ◽  
Sabreena Mohtarin ◽  
Sonchita Rani Mudi ◽  
Taznuva Anwar ◽  
Laila Anjuman Banu ◽  
...  

This study examined whether circulating levels of soluble receptor for advanced glycation end products (sRAGE) alter in prediabetes and correlate with insulin resistance (IR) and beta cell function in prediabetes and newly diagnosed type 2 diabetes mellitus (T2DM). Subjects without previous history of diabetes were recruited and grouped as control, prediabetes, and newly diagnosed T2DM. The control subjects (n=40) and people with prediabetes (n=52) and diabetes (n=66) were similar in terms of age, sex, BMI, systolic and diastolic BP, and fasting insulin level. HOMA-IR was found significantly higher in people with diabetes than control subjects (p<0.001) and people with prediabetes (p=0.005); and HOMA-%B was found significantly deteriorated in people with diabetes (p<0.001) compared to control subjects and people with prediabetes. However, serum sRAGE levels did not show any significant alteration in people with prediabetes compared to control subjects. Moreover, univariate and multivariate analyses did not identify any significant correlation and statistical association of sRAGE with HOMA-IR and HOMA-%B in people with prediabetes and newly diagnosed T2DM. Our data suggest that serum sRAGE levels do not alter in people with prediabetes compared to control subjects and do not correlate or associate with IR and beta cell function during development of T2DM.


2015 ◽  
Vol 24 (10) ◽  
pp. 3004-3004 ◽  
Author(s):  
L. Shu ◽  
A. V. Matveyenko ◽  
J. Kerr-Conte ◽  
J.-H. Cho ◽  
C. H. S. McIntosh ◽  
...  

2009 ◽  
Vol 18 (13) ◽  
pp. 2388-2399 ◽  
Author(s):  
Luan Shu ◽  
Aleksey V. Matveyenko ◽  
Julie Kerr-Conte ◽  
Jae-Hyoung Cho ◽  
Christopher H.S. McIntosh ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document